尿液蛋白质组学将补体激活与狼疮性肾炎患者的间质纤维化/肾小管萎缩联系起来
该研究纳入46例经活检证实的成人及儿童狼疮性肾炎患者,比较中重度间质纤维化/肾小管萎缩(IFTA)与无/轻度IFTA患者的尿液补体成分及C9与CD59比值。中重度IFTA患者尿液C9与CD59比值、C3和CFI水平均升高,且这些补体蛋白与促纤维化因子TGFβR1、PDGFβ、PDGFRβ相关。研究提示C3、CFI和C9与CD59比值可能是狼疮性肾炎肾小管间质纤维化的潜在标志物。
要点
- 中重度IFTA患者尿液C9与CD59比值中位数0.91,无/轻度IFTA患者为0.81,p=0.01。
- 中重度IFTA患者尿液C3中位数24.4,无/轻度IFTA患者为20.2,p=0.02。
- 中重度IFTA患者尿液CFI中位数28.8,无/轻度IFTA患者为20.4,p=0.01。
核心结论
- 该研究比较了人组织中间质纤维化/肾小管萎缩中重度与无/轻度狼疮性肾炎患者的尿液补体谱,鉴定出C3、CFI和C9与CD59比值作为狼疮性肾炎肾小管间质纤维化的潜在标志物。
研究设计与样本
- 纳入2010年至2019年间因临床指征接受肾活检的46例经活检证实的成人及儿童狼疮性肾炎患者的尿液样本。
- 采用质谱(Orbitrap Fusion Lumos,Thermo Scientific)进行蛋白质组学分析,并用Proteome Discoverer处理数据。
- 比较中重度IFTA与无/轻度IFTA狼疮性肾炎患者之间的个体尿液补体成分及尿液C9与CD59比值。
主要发现
- 46例狼疮性肾炎患者中,41例(89.1%)为女性,20例(43.5%)自认为西班牙裔或拉丁裔,26例(56.5%)自认为黑人或非裔美国人。
- 46例狼疮性肾炎患者中10例(21.7%)肾活检显示中重度IFTA。
- 中重度IFTA的狼疮性肾炎患者尿液C9与CD59比值升高[中位数0.91(0.83-1.05)vs 0.81(0.76-0.91),p=0.01]。
- 中重度IFTA的狼疮性肾炎患者尿液C3和CFI水平高于无/轻度IFTA患者[C3中位数(IQR)24.4(23.5-25.5)vs 20.2(18.5-22.2),p=0.02],[CFI中位数(IQR)28.8(21.8-30.6)vs 20.4(18.5-22.9),p=0.01]。
- 补体C9、CD59、C3和CFI与TGFβR1、PDGFβ和PDGFRβ相关,而C9、CD59和C3与TGFβR2相关。
关键数值与推荐
- IFTA定义为无/轻度(间质受累<25%)与中重度(间质受累≥25%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intrarenal complement activation has been implicated in the pathogenesis of tubulointerstitial fibrosis in lupus nephritis (LN) based on prior animal studies. The assembly of the membrane attack complex (MAC) by complement C5b to C9 on the cell membrane leads to cytotoxic pores and cell lysis, while CD59 inhibits MAC formation by preventing C9 from joining the complex. We hypothesize that complement activation and imbalance between complement activation and inhibition, as defined by increased production of individual complement components and uncontrolled MAC activation relative to CD59 inhibition, are associated with interstitial fibrosis and tubular atrophy (IFTA) in LN and correlate with the key mediators of kidney fibrosis- transforming growth factor receptors beta (TGFRβ), platelet-derived growth factor beta (PDGFβ) and platelet-derived growth factor receptor beta (PDGFRβ). METHODS: We included urine samples from 46 adults and pediatric biopsy-proven lupus nephritis patients who underwent clinically indicated kidney biopsies between 2010 and 2019. We compared individual urinary complement components and the urinary C9-to-CD59 ratio between LN patients with moderate/severe IFTA and none/mild IFTA. IFTA was defined as none/mild (<25% of interstitium affected) versus moderate/severe (≥ 25% of interstitium affected). Proteomics analysis was performed using mass spectrometry (Orbitrap Fusion Lumos, Thermo Scientific) and processed by the Proteome Discoverer. Urinary complement proteins enriched in LN patients with moderate/severe IFTA were correlated with serum creatinine, TGFβR1, TGFβR2, PDGFβ, and PDGFRβ. RESULTS: Of the 46 LN patients included in the study, 41 (89.1%) were women, 20 (43.5%) self-identified as Hispanic or Latino, and 26 (56.5%) self-identified as Black or African American. Ten of the 46 (21.7%) LN patients had moderate/severe IFTA on kidney biopsy. LN patients with moderate/severe IFTA had an increased urinary C9-to-CD59 ratio [median 0.91 (0.83-1.05) vs 0.81 (0.76-0.91), p=0.01]. Urinary C3 and CFI levels in LN patients with moderate/severe IFTA were higher compared to those with none/mild IFTA [C3 median (IQR) 24.4(23.5-25.5) vs. 20.2 (18.5-22.2), p= 0.02], [CFI medium (IQR) 28.8 (21.8-30.6) vs. 20.4 (18.5-22.9), p=0.01]. Complement C9, CD59, C3 and CFI correlated with TGFβR1, PDGFβ, and PDGFRβ, while C9, CD59 and C3 correlated with TGFβR2. CONCLUSION: This study is one of the first to compare the urinary complement profile in LN patients with moderate/severe IFTA and none/mild IFTA in human tissues. This study identified C3, CFI, and C9-to-CD59 ratio as potential markers of tubulointerstitial fibrosis in LN.
引用
- Wang S, Broder A, Shao D, et al. Urine Proteomics Link Complement Activation with Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients. Semin Arthritis Rheum. 2023. PMID: 37802003. doi:10.1016/j.semarthrit.2023.152263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。